Health
Synairgen’s SNG001 advances into phase 3 COVID-19 trial – PMLiVE
UK biotech had initially been testing drug for COPD and asthma
Southampton, UK-based biotech company Synairgen has announced that a small phase 2 trial of its investigational candidate SNG001 supports advancement into phase 3 testing.
SNG001 delivers an inhaled formulation of Interferon-beta-1a (INF-beta-1a) to the lungs directly via nebulisation – INF-beta is a naturally occurring protein that controls the body’s antiviral response.
Initially, Synairgen had been evaluating the drug as a treatment for COPD and asthma, although its focus has now shifted to investigating…
-
Noosa News21 hours agoTwo trapped and fighting for life after major three-vehicle crash in Brisbane
-
Business22 hours agoUp 105% in a year, are Pro Medicus shares still a good buy today?
-
Business21 hours agoEverything you need to know about the Coles dividend
-
Noosa News18 hours agoQueensland man sentenced to four years imprisonment after string of terror offences